crc01
High-grade B-cell Lymphoma
Curocell Inc.Phase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
89 Active assets in the High-grade B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BB |
Ifosfamide University of California, Davis | Phase 3 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
crc01 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →